Agomab (AGMB)
9.13
+0.02 (0.22%)
Upcoming Events
Latest Headlines
Form 4 AgomAb Therapeutics NV For: Oct 21 Filed by: Epstein David R
October 22, 2026 8:15 AM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Agomab Therapeutics (AGMB)
October 21, 2026 6:51 AM - StreetInsider
Form 6-K AgomAb Therapeutics NV For: Oct 13
October 13, 2026 5:19 PM - SEC Filing
Agomab doses first patient in Phase 2b Crohn's disease study
October 13, 2026 4:05 PM - StreetInsider
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
October 13, 2026 4:05 PM - Globe NewsWire
Form 4 AgomAb Therapeutics NV For: Oct 08 Filed by: Epstein David R
October 9, 2026 8:01 AM - SEC Filing
Form 4 AgomAb Therapeutics NV For: Oct 05 Filed by: Epstein David R
October 7, 2026 8:57 AM - SEC Filing
Form 4 AgomAb Therapeutics NV For: Oct 06 Filed by: Kemula Pierre Thadee Victor
October 7, 2026 8:47 AM - SEC Filing
Form 4 AgomAb Therapeutics NV For: Oct 05 Filed by: Knotnerus Tim Jasper
October 7, 2026 8:07 AM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Agomab Therapeutics (AGMB)
October 2, 2026 6:59 AM - StreetInsider
Agomab stock jumps on positive trial data
October 1, 2026 9:05 AM - StreetInsider
Form 6-K AgomAb Therapeutics NV For: Oct 01
October 1, 2026 6:42 AM - SEC Filing
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
October 1, 2026 6:30 AM - Globe NewsWire
H.C. Wainwright Reiterates Buy Rating on Agomab Therapeutics (AGMB)
September 16, 2026 6:58 AM - StreetInsider
Form 4 AgomAb Therapeutics NV For: Sep 11 Filed by: Garcia Marino
September 15, 2026 4:07 PM - SEC Filing
Form 4 AgomAb Therapeutics NV For: Sep 11 Filed by: Patel Naimish
September 15, 2026 4:06 PM - SEC Filing
Form 3 AgomAb Therapeutics NV For: Sep 11 Filed by: Garcia Marino
September 15, 2026 4:06 PM - SEC Filing
Form 3 AgomAb Therapeutics NV For: Sep 11 Filed by: Patel Naimish
September 15, 2026 4:06 PM - SEC Filing
Form 6-K Agomab Therapeutics NV For: Sep 14
September 14, 2026 4:15 PM - SEC Filing
Form 6-K Agomab Therapeutics NV For: Sep 11
September 11, 2026 5:03 PM - SEC Filing
Agomab adds two members to its board of directors
September 11, 2026 4:05 PM - StreetInsider
Agomab adds two members to its board of directors
September 11, 2026 4:05 PM - StreetInsider
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
September 11, 2026 4:05 PM - Globe NewsWire
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
September 11, 2026 4:05 PM - StreetInsider
Agomab to Participate in Upcoming Investor Conferences
September 3, 2026 4:05 PM - StreetInsider
Piper Sandler Starts Agomab Therapeutics (AGMB) at Overweight
August 25, 2026 4:06 AM - StreetInsider
Cantor Fitzgerald Starts Agomab Therapeutics (AGMB) at Overweight
August 19, 2026 6:13 AM - StreetInsider
Form 6-K Agomab Therapeutics NV For: Aug 10
August 10, 2026 4:19 PM - SEC Filing
Agomab proposes two new board members ahead of shareholder vote
August 10, 2026 4:08 PM - StreetInsider
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
August 10, 2026 4:08 PM - StreetInsider
Agomab proposes two new board members ahead of shareholder vote
August 10, 2026 4:07 PM - StreetInsider
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
August 10, 2026 4:07 PM - Globe NewsWire
Form 6-K Agomab Therapeutics NV For: Aug 06
August 6, 2026 4:08 PM - SEC Filing
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
August 6, 2026 4:01 PM - StreetInsider
Full Article List
